Cardiovascular effects of a PEGylated apelin

Peptides

Volumn 38, Issue 1, 2012, Pages 181-188

  Jia, Z Q ^a   Hou, L ^b   Leger, A ^a   Wu, I ^a   Kudej, A B ^a   Stefano, J ^b   Jiang, C ^a,c   Pan, C Q ^b   Akita, G Y ^a  

^a SANOFI   (France)

^b Alcon Laboratories Inc ^*  (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

Apelin; Cardiac function; Inotropic effect; PEGylation; Rat

Indexed keywords

ADENYLATE CYCLASE INHIBITOR; APELIN; APELIN 36; APELIN RECEPTOR; CARDIOVASCULAR AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; BINDING AFFINITY; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG PURITY; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA; RATTUS;

EID: 84866714190     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2012.09.003     Document Type: Article

References (22)

1. E.A. Ashley, J. Powers, M. Chen, R. Kundu, T. Finsterbach, and A. Caffarelli The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo Cardiovasc Res 65 2005 73 82
2. G. Barnes, A.G. Japp, and D.E. Newby Translational promise of the apelin-APJ system Heart 96 2010 1011 1016
3. M.F. Berry, T.J. Pirolli, V. Jayasankar, J. Burdick, K.J. Morine, and T.J. Gardner Apelin has in vivo inotropic effects on normal and failing hearts Circulation 110 2004 II187 II193
4. C.J. Charles, M.T. Rademaker, and A.M. Richards Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep J Endocrinol 189 2006 701 710
5. X. Cheng, X.S. Cheng, and C.C. Pang Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats Eur J Pharmacol 470 2003 171 175
6. T. Dai, G. Ramirez-Correa, and W.D. Gao Apelin increases contractility in failing cardiac muscle Eur J Pharmacol 553 2006 222 228
7. N. De Mota, A. Reaux-Le Goazigo, S. El Messari, N. Chartrel, D. Roesch, and C. Dujardin Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release Proc Natl Acad Sci USA 101 2004 10464 10469
8. S. El Messari, X. Iturrioz, C. Fassot, N. De Mota, D. Roesch, and C. Llorens-Cortes Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure J Neurochem 90 2004 1290 1301
9. I. Falcao-Pires, N. Goncalves, T. Henriques-Coelho, D. Moreira-Goncalves, R. Roncon-Albuquerque Jr., and A.F. Leite-Moreira Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension Am J Physiol Heart Circ Physiol 296 2009 H2007 H2014
10. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat Rev Drug Discov 2 2003 214 221
11. A.G. Japp, N.L. Cruden, D.A. Amer, V.K. Li, E.B. Goudie, and N.R. Johnston Vascular effects of apelin in vivo in man J Am Coll Cardiol 52 2008 908 913
12. A.G. Japp, N.L. Cruden, G. Barnes, N. van Gemeren, J. Mathews, and J. Adamson Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure Circulation 121 2010 1818 1827
13. S. Kagiyama, M. Fukuhara, K. Matsumura, Y. Lin, K. Fujii, and M. Iida Central and peripheral cardiovascular actions of apelin in conscious rats Regul Pept 125 2005 55 59
14. M.J. Kleinz, and G.F. Baxter Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase Regul Pept 146 2008 271 277
15. M.J. Kleinz, and A.P. Davenport Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells Regul Pept 118 2004 119 125
16. D.K. Lee, R. Cheng, T. Nguyen, T. Fan, A.P. Kariyawasam, and Y. Liu Characterization of apelin, the ligand for the APJ receptor J Neurochem 74 2000 34 41
17. H. Lee, I.H. Jang, S.H. Ryu, and T.G. Park N-terminal site-specific mono-PEGylation of epidermal growth factor Pharm Res 20 2003 818 825
18. M.J. Roberts, M.D. Bentley, and J.M. Harris Chemistry for peptide and protein PEGylation Adv Drug Deliv Rev 54 2002 459 476
19. J.C. Simpkin, D.M. Yellon, S.M. Davidson, S.Y. Lim, A.M. Wynne, and C.C. Smith Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia reperfusion injury Basic Res Cardiol 102 2007 518 528
20. C.C. Smith, M.M. Mocanu, J. Bowen, A.M. Wynne, J.C. Simpkin, and R.A. Dixon Temporal changes in myocardial salvage kinases during reperfusion following ischemia: studies involving the cardioprotective adipocytokine apelin Cardiovasc Drugs Ther 21 2007 409 414
21. I. Szokodi, P. Tavi, G. Foldes, S. Voutilainen-Myllyla, M. Ilves, and H. Tokola Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility Circ Res 91 2002 434 440
22. K. Tatemoto, M. Hosoya, Y. Habata, R. Fujii, T. Kakegawa, and M.X. Zou Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor Biochem Biophys Res Commun 251 1998 471 476